Physician profile
Ruth E Wermont
NPI 1629047287
$6,691.99
in general payments reported to CMS, 2019-2025
37 companies · $98.32 in 2025
The $98.32 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,527 · 2022: $1,526 · 2023: $2,001 · 2024: $1,541 · 2025: $98.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,578 · Education: $61.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,577.78 |
| Education | $61.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $672.12 | 2021-2024 | Tymlos |
| Novo Nordisk INC | $609.40 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $601.15 | 2021-2024 | Mounjaro, Emgality, Jardiance |
| Amgen INC. | $566.14 | 2021-2024 | Evenity, Prolia, Repatha |
| Abbvie INC. | $478.18 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $471.25 | 2021-2024 | |
| Glaxosmithkline, LLC. | $454.21 | 2021-2023 | Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $283.85 | 2021-2024 | Airsupra, Breztri |
| Astellas Pharma US INC | $276.03 | 2021-2024 | Myrbetriq, Veozah |
| Abbott Laboratories | $255.71 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Esperion Therapeutics, INC. | $244.03 | 2021-2024 | Nexletol |
| Pfizer INC. | $240.20 | 2021-2024 | |
| Idorsia Pharmaceuticals US INC | $167.55 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $154.78 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $147.71 | 2022-2023 | Vaxneuvance, Gardasil 9, Pneumovax 23 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Wermont listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.